No Picture
News

Halozyme Announces First Clinical Dosing In argenx’s Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology

SAN DIEGO, July 17, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial … […]

No Picture
News

TMRW Robotic Process Automation Platform Goes Live at San Diego Fertility Center, Vios Fertility Institute – Chicago and Reproductive Medicine Associates of New York

Multi-Site Study to Track Improvements to Safety and Results Achieved through Process Automation for the Preservation of Embryos and Other Fertility Cells

NEW YORK and CHICAGO and SAN DIEGO, July 16, 2019 /PRNewswire/ — TMRW, the creator of the firs… […]